Vericel Corp. (VCEL)
37.38
+0.35
(+0.95%)
USD |
NASDAQ |
Jun 10, 16:00
37.44
+0.06
(+0.16%)
After-Hours: 20:00
Vericel Enterprise Value : 1.858B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 1.858B |
| June 09, 2026 | 1.840B |
| June 08, 2026 | 1.776B |
| June 05, 2026 | 1.803B |
| June 04, 2026 | 1.772B |
| June 03, 2026 | 1.723B |
| June 02, 2026 | 1.708B |
| June 01, 2026 | 1.625B |
| May 29, 2026 | 1.651B |
| May 28, 2026 | 1.698B |
| May 27, 2026 | 1.701B |
| May 26, 2026 | 1.737B |
| May 22, 2026 | 1.725B |
| May 21, 2026 | 1.746B |
| May 20, 2026 | 1.759B |
| May 19, 2026 | 1.712B |
| May 18, 2026 | 1.732B |
| May 15, 2026 | 1.638B |
| May 14, 2026 | 1.643B |
| May 13, 2026 | 1.628B |
| May 12, 2026 | 1.633B |
| May 11, 2026 | 1.632B |
| May 08, 2026 | 1.660B |
| May 07, 2026 | 1.745B |
| May 06, 2026 | 1.829B |
| Date | Value |
|---|---|
| May 05, 2026 | 1.831B |
| May 04, 2026 | 1.815B |
| May 01, 2026 | 1.768B |
| April 30, 2026 | 1.725B |
| April 29, 2026 | 1.656B |
| April 28, 2026 | 1.770B |
| April 27, 2026 | 1.834B |
| April 24, 2026 | 1.769B |
| April 23, 2026 | 1.706B |
| April 22, 2026 | 1.704B |
| April 21, 2026 | 1.669B |
| April 20, 2026 | 1.778B |
| April 17, 2026 | 1.771B |
| April 16, 2026 | 1.674B |
| April 15, 2026 | 1.755B |
| April 14, 2026 | 1.744B |
| April 13, 2026 | 1.708B |
| April 10, 2026 | 1.670B |
| April 09, 2026 | 1.665B |
| April 08, 2026 | 1.687B |
| April 07, 2026 | 1.651B |
| April 06, 2026 | 1.690B |
| April 02, 2026 | 1.693B |
| April 01, 2026 | 1.612B |
| March 31, 2026 | 1.592B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Marker Therapeutics, Inc. | 8.204M |
| Krystal Biotech, Inc. | 8.382B |
| TG Therapeutics, Inc. | 7.376B |
| Gyre Therapeutics, Inc. | 530.15M |
| ACADIA Pharmaceuticals, Inc. | 2.835B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.302M |
| Revenue (Quarterly) | 68.42M |
| Total Expenses (Quarterly) | 74.73M |
| EPS Diluted (Quarterly) | -0.1241 |
| Gross Profit Margin (Quarterly) | 72.00% |
| Profit Margin (Quarterly) | -9.21% |
| Earnings Yield | 1.09% |
| Operating Earnings Yield | 0.82% |
| Normalized Earnings Yield | 1.094 |